Jingxin Pharma In-licenses China Rights to Insomnia Drug

Zhejiang Jingxin Pharmaceutical has in-licensed the China rights to an insomnia drug candidate from Evotec AG of Germany. Jingxin Pharma will have exclusive China rights to the EVT 201, a novel, clinical-stage insomnia treatment. Evotec will receive a small upfront payment, plus commercial milestones and royalties that Evotec called “significant.” More details.... Stock Symbol: (Frankfurt: EVT)